Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years.

ABSTRACT:

Introduction

Solanezumab is an anti-amyloid monoclonal antibody in clinical testing for treatment of Alzheimer's disease (AD). Its mechanism suggests the possibility of slowing the progression of AD.

Methods

A possible disease-modifying effect of solanezumab was assessed using a new statistical method including noninferiority testing. Performance differences were compared during the placebo-controlled period with performance differences after the placebo patients crossed over to solanezumab in the delayed-start period.

Results

Noninferiority of the 14-item Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog₁₄) and Alzheimer's Disease Cooperative Study Activities of Daily Living inventory instrumental items (ADCS-iADL) differences was met throu

SUBMITTER: Liu-Seifert H 

PROVIDER: S-EPMC5975050 | biostudies-literature | 2015 Sep

REPOSITORIES: biostudies-literature